以NGS为基础的主要疾病和抗微生物抗药性的测试扩大了印度的精确诊断能力。 Genient expands India’s precision diagnostics with NGS-based tests for major diseases and antimicrobial resistance.

以诺伊达为基地的基因组公司Genent正在扩大印度的精确诊断,采用以NGS为主的针对结核病、艾滋病毒、肝炎、败血症和抗微生物抗药性的解决方案。 Genient, a Noida-based genomics company, is expanding precision diagnostics in India with NGS-based solutions targeting tuberculosis, HIV, hepatitis, sepsis, and antimicrobial resistance. 该公司提供病原体检测、抗药性检测和肿瘤学化验,并与Deep Chek-生物信息学平台相结合,进行标准化的国内数据分析。 The company offers pathogen detection, drug resistance testing, and oncology assays, integrated with its DeepChek® bioinformatics platform for standardized, in-country data analysis. 由CEO Brijesh Singh领导的新领导以及本地制造计划,Genient旨在加强印度的诊断基础设施和抗微生物管理。 With new leadership under CEO Brijesh Singh and plans for localized manufacturing, Genient aims to strengthen India’s diagnostic infrastructure and antimicrobial stewardship.